Drug
Apatinib clinical trials
Also written YN968D1 and Rivoceranib.
- studies test it
- 412
- open now
- 94
- in phase 3
- 48
- first study started
- 2007
Keep track of what changes. Save the apatinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Studies by the year they started
412 studies that test it; most in 2017 (64)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 12 |
| 2016 | 48 |
| 2017 | 64 |
| 2018 | 53 |
| 2019 | 51 |
| 2020 | 49 |
| 2021 | 32 |
| 2022 | 14 |
| 2023 | 18 |
| 2024 | 29 |
| 2025 | 18 |
| 2026 | 13 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 57
- Phase 2
- 318
- Phase 3
- 48
- Phase 4
- 9
- No phase
- 20
What it is tested for
Each study’s main condition, where its own words name it.
- Sarcoma
- 11
Who runs them
Industry 48 · Other 364
Jiangsu HengRui Medicine Co., Ltd. (36) · Sun Yat-sen University (23) · Fudan University (19) · Tianjin Medical University Cancer Institute and Hospital (15) · Henan Cancer Hospital (15) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (12) · Fujian Cancer Hospital (12) · Peking University Cancer Hospital & Institute (10)
Often tested with
Tested in the same studies.
Camrelizumab (106) · Adebrelimab (27) · Paclitaxel (26) · Fluzoparib (16) · Etoposide (12) · Oxaliplatin (11) · Albumin-Bound Paclitaxel (11) · Docetaxel (10)
Studies
Open first, then newest update. How each study uses apatinib is read from its arms, and is right about nine times in ten.
Testing it · 412
- Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Treatment for Metastatic GC/GEJCNot yet recruitingPhase 2Fudan UniversityNCT07874425Written as apatinib
- Individualized Comprehensive Treatment for Advanced Hepatocellular CarcinomaRecruitingNot applicableNanjing Tianyinshan HospitalNCT06893887Written as Apatinib
- A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung CancerRecruitingPhase 2Jin YingNCT06483282Written as Apatinib Mesylate
- Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric CancerRecruitingPhase 2The First Affiliated Hospital of Bengbu Medical UniversityNCT03219593Written as Apatinib mesylate tablets
- GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDACNot yet recruitingPhase 1/2West China HospitalNCT07802184Written as Apatinib
- A Clinical Trial With Apatinib for Subjects With Refractory Malignant AscitesRecruitingPhase 2The First Affiliated Hospital of Bengbu Medical UniversityNCT03020979Written as Apatinib
- PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric CancerRecruitingPhase 2The First Affiliated Hospital of Zhengzhou UniversityNCT07294664Written as Apatinib
- A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular InvasionNot yet recruitingPhase 4Zhai WenlongNCT07790419Written as Donafenib + lenvatinib+apatinib
- Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic CancerNot yet recruitingPhase 2Tang-Du HospitalNCT07773363Written as Apatinib
- SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular CarcinomaNot yet recruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07749859Written as Retlirafusp alfa Injection, apatinib
- SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric CancerRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07464756Written as apatinib
- Precision Medicine for Immunotherapy-Resistant Advanced Esophageal CancerNot yet recruitingPhase 2/3Peking University Cancer Hospital & InstituteNCT07653451Written as Camrelizumab + Apatinib
- Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell CarcinomaRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06339619Written as Apatinib
- A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence FactorsNot yet recruitingNot applicableHenan Cancer HospitalNCT07618546Written as Apatinib Mesylate Tablets
- Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction CancerNot yet recruitingPhase 2Henan Cancer HospitalNCT07610629Written as Retlirafusp alfa + Apatinib + Nab-paclitaxel
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as Apatinib
- Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract CancerRecruitingPhase 2Air Force Military Medical University, ChinaNCT07569679Written as Apatinib
- Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast CancerRecruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06889688Written as Camrelizumab+Apatinib+Eribulin
- Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric CancerRecruitingPhase 2Beijing Friendship HospitalNCT07353684Written as Apatinib
- Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal TumorRecruitingPhase 2Asan Medical CenterNCT05905887Written as Rivoceranib Mesylate, Paclitaxel
See all 412 studies that test apatinib →
Given in every arm · 23 — apatinib is usual care beside what is tested
- Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant TherapyRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06992336Written as Apatinib, Camrelizumab
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll StudyRecruitingPhase 2LaNova Medicines Zhejiang Co., Ltd.NCT05934331Written as Apatinib
- Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBCRecruitingPhase 2The First Affiliated Hospital of Bengbu Medical UniversityNCT05192798Written as Apatinib Mesylate
- A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric CancerRecruitingPhase 2The First Affiliated Hospital of Zhengzhou UniversityNCT07770113Written as Apatinib
- A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular CarcinomaNot yet recruitingPhase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07682272Written as Apatinib Mesylate Tablets
- ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCCRecruitingPhase 2Peking Union Medical College HospitalNCT07157969Written as Apatinib
- Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular CarcinomaRecruitingPhase 3The First Affiliated Hospital with Nanjing Medical UniversityNCT05613478Written as Apatinib Mesylate
- Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.Not yet recruitingPhase 2The First Affiliated Hospital of Henan University of Science and TechnologyNCT06464614Written as Apatinib
- Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC PatientsRecruitingPhase 2Shanghai Jiao Tong University School of MedicineNCT05069857Written as Apatinib (anti-VEGFR inhibitor)
- Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized TrialActive, not recruitingPhase 3Sun Yat-sen UniversityNCT05198609Written as Apatinib
- A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric CancerCompletedPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT03472365Written as Apatinib
- Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapyActive, not recruitingPhase 2Ruijin HospitalNCT03742193Written as Apatinib
- Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric CancerStatus unknownPhase 2Sixth Affiliated Hospital, Sun Yat-sen UniversityNCT05342389Written as Apatinib Mesylate
- Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric CancerStatus unknownPhase 2Fudan UniversityNCT05095636Written as Apatinib Mesylate
- SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell CancerStatus unknownPhase 2Chinese Academy of Medical SciencesNCT03603756Written as Apatinib
- Study of SHR-1210 Combined With Apatinib in the Treatment of SarcomaStatus unknownPhase 2Tianjin Medical University Cancer Institute and HospitalNCT04126993Written as Apatinib
- Study of the Apatinib Combine With POF Versus POF in Gastric CancerStatus unknownPhase 2Fujian Cancer HospitalNCT04121039Written as Apatinib
- Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCCStatus unknownNot applicableTianjin Medical University Cancer Institute and HospitalNCT03671265Written as Apatinib
- The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor ThrombusStatus unknownPhase 2Guangxi Medical UniversityNCT03520257Written as Apatinib
- Study of Apatinib Combined With TACE in Advance Hepatocellular CarcinomaStatus unknownNot applicableTianjin Medical University Cancer Institute and HospitalNCT03398122Written as Apatinib
Showing 20 of 23.
As the comparator · 7 — what is tested is compared with apatinib
- TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular CarcinomaRecruitingPhase 3Guohui XuNCT06485466Written as Camrelizumab and apatinib
- A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular CarcinomaNot yet recruitingPhase 2/3Shanghai Zhongshan HospitalNCT07309419Written as Apatinib
- Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCCRecruitingPhase 3Linhui PengNCT07267806Written as Camrelizumab and apatinib
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionRecruitingPhase 3RemeGen Co., Ltd.NCT04714190Written as Apatinib Mesylate Tablets
- AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2Active, not recruitingPhase 3AstraZenecaNCT06346392Written as Apatinib
- LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.Active, not recruitingPhase 3LaNova Medicines Zhejiang Co., Ltd.NCT06351020Written as Apatinib
- A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)TerminatedPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT04985136Written as Rivoceranib
Codes
What other systems call apatinib · ClinicalTrials.gg INT005736
- MeSH (NLM) C553458apatinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 5S371K6132RIVOCERANIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27262801apatinibConfirmed FDA, NLM, Wikidata
- DrugBank DB14765One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C553458 | apatinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 5S371K6132 | RIVOCERANIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27262801 | apatinib | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB14765 | — | One source Wikidata |
Also registered as rivoceranib mesylate (UNII TK02X14ASJ).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.